Comparative Health Status and Quality of Life of Patients With Sickle Cell Disease (SCD) Who Underwent Matched-sibling Hematopoietic Stem Cell Transplantation Versus Non Transplanted SCD Case-control Patients

Not Applicable

Not yet recruiting

• Conditions: Sickle Cell Disease
• Interventions: Other: Spermogram; Other: Hospital Anxiety and Depression Scale (HADS); Other: SF36 Quality of life questionnaire; Other: Psychologist interview; Other: Optional sera banking; Other: Optional DNA banking

• Registration Number: NCT06351462
• Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Brief Summary

The long term burden of morbidity and mortality in the natural history of sickle cell disease has not been compared up to date to the risks and mortality of a curative option like bone marrow transplantation in severe sickle-cell disease patients. Given this lack of data, primary-care Sickle Cell Disease (SCD) physicians and transplant physicians are prevented from a factual debate over the benefit/risk ratio for each patient and refining indications of transplant in patients. Therefore, the present study seeks to describe and compare the very long-term outcomes after either Human Leukocyte Antigen (HLA) -matched sibling transplantation (study arm) and "non-transplant care" for severe sickle cell disease SCA patients in order to yield robust comparative data regarding both arms.

The main objective is to assess the benefit of Hematopoietic stem cell transplantation (HSCT) regarding quality of life compared to standard care after 10 years, in patients with severe Sickle Cell Disease (SCD).

Detailed Description

Not available

Study Timeline

• Status Verified: 2023-12
• Study First Submitted: 2024-04-02
• Study First Submitted QC: 2024-04-02
• Study First Posted: 2024-04-08
• Last Update Submitted: 2024-04-17
• Last Update Posted: 2024-04-19
• Study Start: 2024-05-01
• Primary Completion: 2027-05-01
• Study Completion: 2027-05-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 220

Inclusion Criteria

Study population (exposed-patients), all criteria should be fulfilled:

1. Patients alive with Sickle Cell Anemia (SCA, meaning SS and Sbeta0 sickle cell anemia genotype)
2. Patients transplanted from allogeneic HLA-compatible sibling donor or from sibling cord blood unit from the 1st of January 2000 and the 31st of December 2012, whatever the age at transplant
3. Patients having received conditioning regimen containing busulfan 1mg/kg/dose (or equivalent adjusted body-weight dosage according to recommendation) x 16 doses + cyclophosphamide 200mg/kg total dose + anti-thymoglobuline
4. For patient under 18 years at time of enrolment, signed informed consent from both parental representatives
5. For patient aged 18 years old : signed informed consent
6. Having an affiliation to a social security regime

Control-population (Non-exposed patients) :

For each allografted patient, one non-exposed patient will be matched, based on the following criteria:

• Gender

• Age at the date of transplantation of the exposed patient (+/- 1 year)

• Foetal hemoglobin (HbF) level (+/- 3%) before treatment intensification (defined as the initiation of either hydroxyurea or a transfusion program)

• Hb level (+/- 0,9 g/dl) before treatment intensification

  1. For patient under 18 years at time of enrolment, signed informed consent from both parental representatives
  2. For patient above 18 years of age: signed informed consent
  3. Having an affiliation of to a social security regime

Read More

Exclusion Criteria

Study population:

• Transplantation from donor other than sibling or related cord-blood
• Conditioning regimen other than busulfan 16mg/kg total dose + cyclophosphamide 200mg/kg total dose + anti-thymoglobuline

For both population:

• Absence of signed informed consent
• Having any debilitating medical or psychiatric illness, which preclude understanding of the inform consent as well as optimal treatment and follow-up

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Controlled patients - not transplanted	Spermogram	-
Controlled patients - not transplanted	Optional sera banking	-
Patients transplanted from allogeneic HLA-compatible sibling donor or from sibling cord blood unit	SF36 Quality of life questionnaire	-
Patients transplanted from allogeneic HLA-compatible sibling donor or from sibling cord blood unit	Optional DNA banking	-
Patients transplanted from allogeneic HLA-compatible sibling donor or from sibling cord blood unit	Spermogram	-
Patients transplanted from allogeneic HLA-compatible sibling donor or from sibling cord blood unit	Psychologist interview	-
Controlled patients - not transplanted	Psychologist interview	-
Controlled patients - not transplanted	Optional DNA banking	-
Controlled patients - not transplanted	Hospital Anxiety and Depression Scale (HADS)	-
Controlled patients - not transplanted	SF36 Quality of life questionnaire	-
Patients transplanted from allogeneic HLA-compatible sibling donor or from sibling cord blood unit	Hospital Anxiety and Depression Scale (HADS)	-
Patients transplanted from allogeneic HLA-compatible sibling donor or from sibling cord blood unit	Optional sera banking	-

Primary Outcome Measures

Name	Time	Method
Evaluation of quality of life assessed by SF36	10 years after HSCT	It will be assessed by the Short-form 36 (SF36) scale. The Short Form (36) Health Survey is a 36-item measure if health status. The score obtained varies between 0 and 100. The higher the score the less disability.; Ware JE, Sherbourne CD. The Medical Outcomes Study 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992;30:473-83.

Secondary Outcome Measures

Name	Time	Method
Proportion of patients with anxiety and depression	10 years after HSCT	Anxiety and depression levels will be assessed using the Hamilton Anxiety Depression scale : The HAD scale is a self-assessment scale for detecting states of depression and anxiety in the setting of an hospital medical outpatient clinic.; HADS is a self-administered scale of 14 items which assessed levels of depression and anxiety, divided into 2 subscales of 7 items (Anxiety or HADS-A, Depression or HADS-D). Each item is scored on a scale of 0 to 3. A score is generated for each of the two sub-scales (sum of the 7 items, ranging from 0 to 21). Limit scores, for each of the scores, distinguish: non-cases or asymptomatic ones (score ≤ 7); probable or borderline cases (score 8-10); clearly or clinically symptomatic cases (score ≥ 11)
Evaluation of gonadal function	10 years after HSCT	Spermogram in men (proposed not requested), Luteinising Hormone (LH), Follicle-Stimulating Hormone (FSH), estrogen, Anti-Müllerian Hormone (AMH) in women, testosterone in men, Amenorrhea in women.
Evaluation of quality of life	10 years after HSCT	Questionnaire including data about employment, education level, social financial support.